LLY
1,064.63
+0.2%↑
JNJ
208.64
-0.99%↓
ABBV
227.15
+0.59%↑
UNH
332.67
+1.59%↑
AZN
91.36
+0.93%↑
LLY
1,064.63
+0.2%↑
JNJ
208.64
-0.99%↓
ABBV
227.15
+0.59%↑
UNH
332.67
+1.59%↑
AZN
91.36
+0.93%↑
LLY
1,064.63
+0.2%↑
JNJ
208.64
-0.99%↓
ABBV
227.15
+0.59%↑
UNH
332.67
+1.59%↑
AZN
91.36
+0.93%↑
LLY
1,064.63
+0.2%↑
JNJ
208.64
-0.99%↓
ABBV
227.15
+0.59%↑
UNH
332.67
+1.59%↑
AZN
91.36
+0.93%↑
LLY
1,064.63
+0.2%↑
JNJ
208.64
-0.99%↓
ABBV
227.15
+0.59%↑
UNH
332.67
+1.59%↑
AZN
91.36
+0.93%↑
24h
Corrente
Minimo
42.59
Massimo
45.99
Entrata | 6.1M -36M |
|---|---|
Vendite | 615K 12M |
EPS | -1.87 |
Margine di Profitto | -301.289 |
Dipendenti | 61 |
EBITDA | 6.9M -29M |
Raccomandazioni | Acquista |
|---|---|
Previsioni per 12 mesi | +128.66% upside |
Capitalizzazione di Mercato | -55M 1.1B |
|---|---|
Apertura precedente | 46.9 |
Chiusura precedente | 43.94 |
By Trading Central
Fiducia
Strong Bearish Evidence
0.5949 / 0.7406 Supporto e resistenza
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
18 dic 2025, 23:54 UTC
Stocks to Watch: Nike, Cassava Sciences, KB Home
DJ
LeggI
18 dic 2025, 23:51 UTC
Nike Sales Tick Up in 2Q; China Weakness Persists -- Update
DJ
LeggI
18 dic 2025, 23:39 UTC
Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial
DJ
LeggI
18 dic 2025, 22:57 UTC
TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo
DJ
LeggI
18 dic 2025, 21:40 UTC
Nike Sales Tick Up, But China Weakness Persists
DJ
LeggI
18 dic 2025, 23:45 UTC
Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk
DJ
LeggI
18 dic 2025, 23:37 UTC
Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk
DJ
LeggI
18 dic 2025, 23:36 UTC
Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk
DJ
LeggI
18 dic 2025, 23:03 UTC
Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial
DJ
LeggI
18 dic 2025, 23:02 UTC
Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.
DJ
LeggI
18 dic 2025, 23:00 UTC
Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.
DJ
LeggI
18 dic 2025, 22:59 UTC
Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material
DJ
LeggI
18 dic 2025, 22:58 UTC
SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com
DJ
LeggI
18 dic 2025, 22:57 UTC
Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.
DJ
LeggI
18 dic 2025, 22:56 UTC
Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD
DJ
LeggI
18 dic 2025, 22:55 UTC
Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com
DJ
LeggI
18 dic 2025, 21:59 UTC
Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com
DJ
LeggI
18 dic 2025, 21:50 UTC
Tech, Media & Telecom Roundup: Market Talk
DJ
LeggI
18 dic 2025, 21:50 UTC
Basic Materials Roundup: Market Talk
DJ
LeggI
18 dic 2025, 21:35 UTC
FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com
DJ
LeggI
18 dic 2025, 21:31 UTC
Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com
DJ
LeggI
18 dic 2025, 21:15 UTC
Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE
DJ
LeggI
18 dic 2025, 21:15 UTC
Nike 2Q Greater China Rev Down 17% >NKE
DJ
LeggI
18 dic 2025, 21:15 UTC
Nike 2Q EPS 53c >NKE
DJ
LeggI
18 dic 2025, 21:15 UTC
Nike 2Q Apparel Rev $3.91B >NKE
DJ
LeggI
18 dic 2025, 21:15 UTC
Nike 2Q Equipment Rev $550M >NKE
DJ
LeggI
18 dic 2025, 21:15 UTC
Nike 2Q N Amer Rev $5.63B >NKE
DJ
LeggI
18 dic 2025, 21:15 UTC
Nike 2Q Footwear Rev $7.66B >NKE
DJ
LeggI
18 dic 2025, 21:15 UTC
Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE
DJ
LeggI
18 dic 2025, 21:15 UTC
Nike 2Q Greater China Rev $1.42B >NKE
DJ
LeggI
Modifica del prezzo
By TipRanks
Previsioni per 12 mesi
Media 103.88 USD 128.66%
Alto 135 USD
Basso 30 USD
Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Nektar Therapeutics - Dist negli ultimi 3 mesi.
By TipRanks
Acquista
9 ratings
7
Acquista
1
Mantieni
1
Vendi
Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Nektar Therapeutics - Dist negli ultimi 3 mesi.
By Trading Central
A breve termine
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
A termine intermedio
Strong Bearish Evidence
All events are bearish.
A lungo termine
Bearish Evidence
All events are bearish.
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$